Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

121. A continuous heparin infusion does not prevent catheter-related thrombosis in infants after cardiac surgery

A continuous heparin infusion does not prevent catheter-related thrombosis in infants after cardiac surgery PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2011

122. Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study

Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study 20719465 2010 12 14 2011 04 06 2016 11 25 1097-6809 52 6 2010 Dec Journal of vascular surgery J. Vasc. Surg. Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study. 1505-10 10.1016/j.jvs.2010.06.098 General recommendations indicate (...) that, during a carotid artery stenting (CAS), sufficient unfractionated heparin (UFH) has to be given to maintain the activated clotting time between 250 to 300 seconds. Bivalirudin use is able to reduce postprocedural bleedings in percutaneous interventions when compared with UFH. The study purpose was to evaluate, in a randomized study, the safety and efficacy of bivalirudin versus heparin during CAS, using proximal endovascular occlusion (PEO) as a distal protection device. From January 2006 to December

EvidenceUpdates2011

123. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy

Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy 20973685 2010 10 26 2011 03 03 2016 11 25 1875-9114 30 11 2010 Nov Pharmacotherapy Pharmacotherapy Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. 1117-26 10.1592/phco.30.11.1117 To evaluate the safety and efficacy of bivalirudin compared with heparin for preventing hemofilter occlusion during (...) continuous venovenous hemofiltration (CVVH). Prospective, randomized, double-blind study. University-affiliated hospital. Ten critically ill adults (median age 58 yrs, 70% male) with acute renal failure who, without anticoagulation, experienced hemofilter survival time of 24 hours or less during CVVH. Patients were randomized to receive bivalirudin 2 mg/hour (five patients) or heparin 400 units/hour (five patients) administered prefilter into the extracorporeal circuit. Patients had a median Acute

EvidenceUpdates2011

124. Randomised controlled trial: Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fon

Randomised controlled trial: Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fon Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinux (...) coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinux Article Text Therapeutics Randomised controlled trial Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated

Evidence-Based Medicine (Requires free registration)2011

125. Cochrane systematic review: Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis

Cochrane systematic review: Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis Article Text Therapeutics Cochrane systematic review Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis Daniel C Baumgart

Evidence-Based Medicine (Requires free registration)2011

126. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients

Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients Individual patient data meta-analysis of enoxaparin vs unfractionated heparin for venous thromboembolism prevention in medical patients Individual patient data meta-analysis of enoxaparin vs unfractionated heparin for venous thromboembolism prevention in medical patients Laporte S, Liotier J, Bertoletti L, Kleber FX, Pineo GF, Chapelle C, Moulin N, Mismetti P (...) CRD summary This individual patient data review concluded that subcutaneous enoxaparin 4000IU reduced the risk of venous thromboembolism in hospitalised medical patients compared with unfractionated heparin without a significant increase in major bleeding. The conclusion about reduced risk is likely to be reliable (but may not be generalisable). The conclusion about major bleeding does not fully reflect the uncertainty in the evidence. Authors' objectives To evaluate the relative efficacy

DARE.2011

127. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis

Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis Kodumuri V, Adigopula S, Singh P, Swaminathan P, Arora R, Khosla S CRD summary This review found (...) that efficacy and bleeding risk of low-weight molecular heparin in patients who underwent percutaneous coronary interventions were similar to those observed with unfractionated heparin. Methodological flaws and the unknown quality of the included studies mean that the authors' conclusions should be interpreted with caution. Authors' objectives To evaluate the efficacy and safety of low-molecular weight heparin (LMWH) compared to unfractionated heparin in patients undergoing percutaneous coronary

DARE.2011

128. Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials

Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis (...) of randomized clinical trials Lee MS, Liao H, Yang T, Dhoot J, Tobis J, Fonarow G, Mahmud E CRD summary This review found that anticoagulation with bivalirudin resulted in a reduction in major bleeding episodes but otherwise similar ischaemic events compared to use of unfractionated heparin or enoxaparin with glycoprotein IIb/IIIa inhibitors. Methodological or reporting flaws mean the results and authors' conclusions may not be reliable. Authors' objectives To assess the safety and efficacy of bivalirudin compared

DARE.2011

129. Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies

Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies Bidlingmaier C, Kenet G, Kurnik K, Mathew P, Manner D, Mitchell L (...) , Krümpel A, Nowak-Gottl U CRD summary This review concluded that the primary prophylaxis, and treatment of venous and arterial thrombosis, with low molecular weight heparins was safe and effective in children aged 18 years and under. The unknown quality of the included studies and methodological flaws means the authors conclusions may not be reliable and are not entirely consistent with the results. Authors' objectives To evaluate the use of low-molecular weight heparins as primary prophylaxis

DARE.2011

130. Dalteparin versus unfractionated heparin in critically ill patients.

Dalteparin versus unfractionated heparin in critically ill patients. 21417952 2011 04 07 2011 04 11 2013 11 21 1533-4406 364 14 2011 Apr 07 The New England journal of medicine N. Engl. J. Med. Dalteparin versus unfractionated heparin in critically ill patients. 1305-14 10.1056/NEJMoa1014475 The effects of thromboprophylaxis with low-molecular-weight heparin, as compared with unfractionated heparin, on venous thromboembolism, bleeding, and other outcomes are uncertain in critically ill patients (...) . In this multicenter trial, we tested the superiority of dalteparin over unfractionated heparin by randomly assigning 3764 patients to receive either subcutaneous dalteparin (at a dose of 5000 IU once daily) plus placebo once daily (for parallel-group twice-daily injections) or unfractionated heparin (at a dose of 5000 IU twice daily) while they were in the intensive care unit. The primary outcome, proximal leg deep-vein thrombosis, was diagnosed on compression ultrasonography performed within 2 days after

NEJM2011

131. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. 22077909 2011 11 24 2011 12 09 2016 11 25 1533-4406 365 21 2011 Nov 24 The New England journal of medicine N. Engl. J. Med. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. 1980-9 10.1056/NEJMoa1109596 The combination of glycoprotein IIb/IIIa inhibitors and heparin has not been compared with bivalirudin in studies specifically involving patients with non-ST-segment elevation (...) myocardial infarction undergoing percutaneous coronary intervention (PCI). We compared the two treatments in this patient population. Immediately before PCI, we randomly assigned, in a double-blind manner, 1721 patients with acute non-ST-segment elevation myocardial infarction to receive abciximab plus unfractionated heparin (861 patients) or bivalirudin (860 patients). The study tested the hypothesis that abciximab and heparin would be superior to bivalirudin with respect to the primary composite end point

NEJM2011

132. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. 21665265 2011 06 27 2011 07 18 2016 11 25 1474-547X 377 9784 2011 Jun 25 Lancet (London, England) Lancet Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute (...) within 12 h after onset of symptoms, and were undergoing primary percutaneous coronary intervention. By use of a computerised interactive voice response system, we randomly allocated patients 1:1 to receive bivalirudin or heparin plus a glycoprotein IIb/IIIa inhibitor (GPI; pharmacological randomisation; stratified by previous and expected drug use and study site) and, if eligible, randomly allocated 3:1 to receive a paclitaxel-eluting stent or a bare metal stent (stent randomisation; stratified

Lancet2011

133. Low-molecular-weight heparin and mortality in acutely ill medical patients.

Low-molecular-weight heparin and mortality in acutely ill medical patients. 22204723 2011 12 29 2012 01 05 2013 01 17 1533-4406 365 26 2011 Dec 29 The New England journal of medicine N. Engl. J. Med. Low-molecular-weight heparin and mortality in acutely ill medical patients. 2463-72 10.1056/NEJMoa1111288 Although thromboprophylaxis reduces the incidence of venous thromboembolism in acutely ill medical patients, an associated reduction in the rate of death from any cause has not been shown. We

NEJM2011

134. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.

Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. 21856483 2011 08 22 2011 09 13 2015 06 16 1474-547X 378 9792 2011 Aug 20 Lancet (London, England) Lancet Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. 693-703 10.1016 (...) /S0140-6736(11)60876-3 Primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction has traditionally been supported by unfractionated heparin, which has never been directly compared with a new anticoagulant using consistent anticoagulation and similar antiplatelet strategies in both groups. We compared traditional heparin treatment with intravenous enoxaparin in primary PCI. In a randomised open-label trial, patients presenting with ST-elevation myocardial infarction were

Lancet2011

135. Heparin Sodium Injection

Heparin Sodium Injection Drug Approval Package:Heparin Sodium NDA #201370 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Heparin Sodium Injection USP Company: Pfizer Inc. Application No.: 201370 Approval Date: 07/21/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: June 20, 2012

FDA - Drug Approval Package2011

136. [Biology of haemostasis disorders: testing for antibodies to platelet factor 4 in a patient with heparin - induced thrombocytopenia]

[Biology of haemostasis disorders: testing for antibodies to platelet factor 4 in a patient with heparin - induced thrombocytopenia] Biologie des anomalies de l'hémostase: recherche d'anticorps antifacteur 4 plaquettaire [Biology of haemostasis disorders: testing for antibodies to platelet factor 4 in a patient with heparin – induced thrombocytopenia] Biologie des anomalies de l'hémostase: recherche d'anticorps antifacteur 4 plaquettaire [Biology of haemostasis disorders: testing for antibodies (...) to platelet factor 4 in a patient with heparin – induced thrombocytopenia] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Biologie des anomalies de l'hémostase: recherche d'anticorps antifacteur 4 plaquettaire. [Biology of haemostasis disorders: testing for antibodies to platelet factor 4

Health Technology Assessment (HTA) Database.2011

137. Randomized, Controlled Trial of Individualized Heparin and Protamine Management in Infants Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Randomized, Controlled Trial of Individualized Heparin and Protamine Management in Infants Undergoing Cardiac Surgery With Cardiopulmonary Bypass 21087706 2010 11 22 2011 03 14 2010 11 22 1558-3597 56 22 2010 Nov 23 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Randomized, controlled trial of individualized heparin and protamine management in infants undergoing cardiac surgery with cardiopulmonary bypass. 1794-802 10.1016/j.jacc.2010.06.046 We sought to determine whether (...) infants (younger than 1 year old) had similar clinical benefits with individualized anticoagulation management as older children and adult undergoing cardiopulmonary bypass (CPB). Individualized heparin and protamine management in older children and adults undergoing CPB has been associated with improved clinical outcomes. Ninety infants younger than 1 year of age undergoing CPB were enrolled in a randomized, controlled trial comparing weight-based anticoagulation management using activated clotting

EvidenceUpdates2010

138. A Randomized, Controlled Trial of Heparin Versus Placebo Infusion to Prolong the Usability of Peripherally Placed Percutaneous Central Venous Catheters (PCVCs) in Neonates: The HIP (Heparin Infusion for PCVC) Study

A Randomized, Controlled Trial of Heparin Versus Placebo Infusion to Prolong the Usability of Peripherally Placed Percutaneous Central Venous Catheters (PCVCs) in Neonates: The HIP (Heparin Infusion for PCVC) Study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2010

139. Heparin and related substances for preventing diabetic kidney disease.

Heparin and related substances for preventing diabetic kidney disease. BACKGROUND: Diabetic kidney disease (DKD, also called diabetic nephropathy, DN) is the major cause of end-stage kidney disease (ESKD) in many countries and is associated with increased morbidity and mortality as compared to other causes of kidney disease. One of the pathological changes of DKD is the thickening of the glomerular basement membrane, mesangial expansion and proliferation. The presence of the glycosaminoglycan (...) side chains of heparan sulfate proteoglycan, an important constituent of the glomerular basement membrane, is decreased in DKD proportionally to the increasing degree of proteinuria. Research on animals has suggested that heparin and related substances may prevent glomerular membrane thickening. However, it is not known whether heparin and related substances can prevent the onset of DKD and, therefore, be recommended for primary prevention of this condition. OBJECTIVES: To assess the benefits

Cochrane2010

140. A randomised, controlled trial of heparin in total parenteral nutrition to prevent sepsis associated with neonatal long lines: the Heparin in Long Line Total Parenteral Nutrition (HILLTOP) trial

A randomised, controlled trial of heparin in total parenteral nutrition to prevent sepsis associated with neonatal long lines: the Heparin in Long Line Total Parenteral Nutrition (HILLTOP) trial 20530110 2010 06 25 2010 08 30 2010 06 25 1468-2052 95 4 2010 Jul Archives of disease in childhood. Fetal and neonatal edition Arch. Dis. Child. Fetal Neonatal Ed. A randomised, controlled trial of heparin in total parenteral nutrition to prevent sepsis associated with neonatal long lines: the Heparin (...) in Long Line Total Parenteral Nutrition (HILLTOP) trial. F252-7 10.1136/adc.2009.167403 Infections are common complications of neonatal long lines. Heparin has been shown to prolong the effective duration of neonatal long lines and to reduce the ability of bacteria to adhere to foreign surfaces, but the effect of heparin on rates of infection is uncertain. The goal of this study was to evaluate the effect of heparin on the frequency of episodes of catheter-related sepsis (CRS) in infants receiving

EvidenceUpdates2010